The Division of Cardiovascular Medicine at Vanderbilt has a long and outstanding track record of training cardiovascular scientists in a broad range of disciplines from molecular biophysics and developmental biology to outcomes research. In this competing renewal application, we propose to train 2 pre-doctoral and 5 post- doctoral trainees annually. Pre-doctoral students are identified during the process of application and recruitment to the Integrated Graduate Program at Vanderbilt. They will receive their doctoral degrees from one of several disciplines such as Cell and Developmental Biology, Molecular Physiology and Biophysics, and Pharmacology. Post-doctoral trainees are physician-scientists recruited directly from the Department of Medicine physician-scientist training pathway or from one of the general or advanced cardiology fellowships. In the period since the previous renewal of this award, the institution has continued to invest heavily in the cardiovascular research programs, with recruitment of new faculty and the establishment of new laboratories and research centers. In just the past 2 years, the division has added 11 physician-scientists, including 4 who are alumni of this T32 program. Among these recruitments are senior investigators who are leaders in cardiovascular research and education. NIH support in the division has grown by 55% in the past 18 months. A new center for translational and clinical research in cardiology (VTRACC) was established in 2013, and major new center grants were obtained from PCORI (Mid-South CDRN) and the American Heart Association (Strategically Focused Prevention Research Network). In 2012, Vanderbilt was selected as the national coordinating center of the NIH national CTSA network. Collectively, these developments offer tremendous new opportunities for our cardiovascular research trainees. We have a growing and increasingly competitive applicant pool for training positions here at Vanderbilt. Simultaneously, we have increased diversity in the program over the last cycle, through institutional initiatives and via our allianc with Meharry Medical College and the Association of Black Cardiologists. In the last cycle, 29% of our T32 trainees were from under-represented minority groups. Our trainees publish, move into faculty positions, and attain grant support, all evidence of the success of the program. Through the continuation of this training program, Vanderbilt is poised to make a significant impact on the training of cardiovascular scientists.

Public Health Relevance

We are training the next generation of scientists with expertise in heart and vascular disease. These trainees will make discoveries during and after their training that will improve our understanding of heart and vascular disease and lead to new treatments.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Institutional National Research Service Award (T32)
Project #
5T32HL007411-39
Application #
9720921
Study Section
NHLBI Institutional Training Mechanism Review Committee (NITM)
Program Officer
Scott, Jane
Project Start
1994-09-30
Project End
2021-06-30
Budget Start
2019-07-01
Budget End
2020-06-30
Support Year
39
Fiscal Year
2019
Total Cost
Indirect Cost
Name
Vanderbilt University Medical Center
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
965717143
City
Nashville
State
TN
Country
United States
Zip Code
37203
Gupte, Manisha; Tumuluru, Samvruta; Sui, Jennifer Y et al. (2018) Cardiomyocyte-specific deletion of GSK-3? leads to cardiac dysfunction in a diet induced obesity model. Int J Cardiol 259:145-152
Gupte, Manisha; Umbarkar, Prachi; Lal, Hind (2017) Mechanistic Insights of Empagliflozin-Mediated Cardiac Benefits: Nearing the Starting Line : Editorial to: ""Empagliflozin Improves Left Ventricular Diastolic Dysfunction in a Genetic Model of Type 2 Diabetes"" by N. Hammoudi et al. Cardiovasc Drugs Ther 31:229-232
Bylund, Jeffery B; Trinh, Linh T; Awgulewitsch, Cassandra P et al. (2017) Coordinated Proliferation and Differentiation of Human-Induced Pluripotent Stem Cell-Derived Cardiac Progenitor Cells Depend on Bone Morphogenetic Protein Signaling Regulation by GREMLIN 2. Stem Cells Dev 26:678-693
Guo, Yuanjun; Gupte, Manisha; Umbarkar, Prachi et al. (2017) Entanglement of GSK-3?, ?-catenin and TGF-?1 signaling network to regulate myocardial fibrosis. J Mol Cell Cardiol 110:109-120
Jefferson, Angela L; Liu, Dandan; Gupta, Deepak K et al. (2017) Lower cardiac index levels relate to lower cerebral blood flow in older adults. Neurology 89:2327-2334
Vander Roest, Mark J; Merryman, W David (2017) A developmental approach to induced pluripotent stem cells-based tissue engineered heart valves. Future Cardiol 13:1-4
Bradham, William S; Bell, Susan P; Adkisson, Douglas W et al. (2017) Myocardial T1 Measurement Predicts Beneficial LV Remodeling After Long-Term Heart Failure Therapy. J Card Fail 23:262-265
Bylund, Jeffery B; Hatzopoulos, Antonis K (2016) Differentiation of Atrial Cardiomyocytes from Pluripotent Stem Cells Using the BMP Antagonist Grem2. J Vis Exp :
Bhatia, Nirmanmoh; Lenihan, Daniel; Sawyer, Douglas B et al. (2016) Getting the SCOOP-Survey of Cardiovascular Outcomes From Oncology Patients During Survivorship. Am J Med Sci 351:570-5
Covarrubias, Roman; Chepurko, Elena; Reynolds, Adam et al. (2016) Role of the CD39/CD73 Purinergic Pathway in Modulating Arterial Thrombosis in Mice. Arterioscler Thromb Vasc Biol 36:1809-20

Showing the most recent 10 out of 120 publications